Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy

Deborah H. Charych(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States))

PLoS ONE

July 5, 2017

10.1371/journal.pone.0179431

Cited by 144

Related Papers

Crossing Over During Caenorhabditis elegans Meiosis Requires a Conserved MutS-Based Pathway That Is Partially Dispensable in Budding Yeast

|Genetics|1999|226